Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art

Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art

Bone health represents a major issue in castration-resistant prostate cancer (CRPC) patients with bone metastases; in fact, the frequently prolonged use of hormonal agents causes important modifications in physiological bone turnover and most of these men will develop skeletal-related events (SREs),...

Full description

Bibliographic Details
Main Authors: Veronica Mollica, Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Alessia Cimadamore, Marina Scarpelli, Chiara Bonucci, Elisa Andrini, Costantino Errani, Matteo Santoni, Rodolfo Montironi, Francesco Massari
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
prostate cancer
bone metastasis
CRPC
HSPC
zoledronic acid
bone-targeted agents
Online Access:https://www.mdpi.com/2072-6694/13/3/546

Internet

https://www.mdpi.com/2072-6694/13/3/546

Similar Items